Search

for
Search:

Research

5 / 1000+ results

research A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia

211 citations , May 2013 in “Journal of Nutrition Health & Aging”

This study found that while MK-0773 significantly increased lean body mass in sarcopenic frail elderly women, it did not significantly improve muscle strength or physical function compared to placebo.

research 519 Phase I/IIa clinical trial for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

5 citations , April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology”

This study reports on an ongoing Phase I/IIa clinical trial of ex vivo gene therapy for treating severe Recessive Dystrophic Epidermolysis Bullosa, involving six adult participants with COL7A1 mutations resulting in deficient type VII collagen production.

research 281 Phase I/IIa clinical trial for the treatment of androgenetic alopecia using intradermal injections of cultured autologous dermal sheath cup cells

September 2017 in “Journal of Investigative Dermatology”

This study found that intradermal injections of cultured autologous dermal sheath cup cells for androgenetic alopecia showed hair loss stabilization at 24 months without serious adverse effects and a sustained response in some participants.

research Author’s reply to the comment on: “The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism”

July 2020 in “Journal of The American Academy of Dermatology”

This article discusses the authors’ response to comments on their study about intradermal botulinum toxin's effect on androgenetic alopecia, reporting no new findings.

research Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures

42 citations , January 2019 in “Frontiers in Immunology”

This study identified diltiazem, a calcium channel blocker for hypertension, as a promising repurposed treatment for influenza, enhancing antiviral efficacy when combined with oseltamivir.

View more "phase iia clinical trial" in research →

Community Join

4 / 1000+ results

community People are misunderstanding PP405. 31% response at 8 weeks is better than you think

181 upvotes 1 year ago

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

community The Cure isn't 5 years away; it's already here.

in Research/Science 1005 upvotes 1 year ago

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

community Coegin Pharma to release Follicopeptide (FOL005) by Q2 2025

118 upvotes 2 years ago

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

community The story of RU58841/ PSK3841

in Research 622 upvotes 2 years ago

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

View more "phase iia clinical trial" in community →

Learn

1 / 801 results

learn Osteopontin

signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

View more "phase iia clinical trial" in learn →

Clinics

6 / 13 results

All 13 clinic results →

Experts

— no results

Try a deeper search in experts →